News | June 12, 2014

Philips Vereos Digital PET/CT Has Improved Detector Performance

First digital PET/CT scanner joins suite of molecular imaging solutions

June 12, 2014 — Philips Healthcare recently introduced Vereos PET/CT, the first digital PET/CT (positron emission tomography/computed tomography) scanner, at the 2014 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in St. Louis. In addition to Vereos, Philips showcased a selection of molecular imaging solutions designed to deliver high image quality, critical clinical information and greater connectivity.

The Vereos PET/CT uses digital silicon photomultiplier detectors instead of traditional analog detectors, creating a step change in performance that includes approximately two-times increase in sensitivity gain, volumetric resolution and quantitative accuracy compared to analog systems. These improvements can ultimately be translated into high image quality, increased diagnostic confidence, improved treatment planning and faster workflows.

"From connected devices to data-driven insights, the pace of imaging innovation is allowing us to see more," said Gene Saragnese, chief executive officer, Imaging Systems, Philips. "Molecular imaging technology is leading the way with digital detection and advanced visualization built on insights from those at the heart of care."

Visitors to the Philips booth at SNMMI had the opportunity to interact with Vereos digital PET/CT clinical images and technology using engaging 3-D visualization tools. The experience provided clinicians an understanding of how Vereos can be used to deliver customized care to meet their most pressing needs.

During the SNMMI annual meeting, Philips also hosted a series of three "Innovation Talks" in its booth theater area, spotlighting customers, scientists and industry thought leaders who discussed topics related to the current and future landscape for digital PET, patient-centered imaging and the importance of creating customized workflows to help manage patient care and radiation dose.

Other advanced molecular imaging technology solutions showcased include”

  • iPatient: An advanced platform with an intuitive interface, iPatient helps to facilitate patient-centered imaging, allows for efficient communication between the CT system and injector, and aids in the delivery of appropriate contrast dose and consistent image quality.
  • BrightView XCT: A SPECT/CT system designed entirely for nuclear medicine, BrightView XCT enables low patient dose levels, high-resolution localization and high-quality attenuation correction, for smart assessments and short exams with the patient's comfort in mind.
  • IntelliSpace Portal: Part of Philips' family of clinical information systems within Philips Healthcare’s Informatics Solutions and Services Group, the IntelliSpace Portal offers extensive clinical coverage, streamlined workflow and continuous evolution of advanced visualization and analysis capabilities within a single solution.

For more information: www.philips.com/snmmi

Related Content

Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018
January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...
PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Overlay Init